DK0603769T3 - Alfa-aminoketonderivater - Google Patents

Alfa-aminoketonderivater

Info

Publication number: DK0603769T3
Authority: DK; Denmark
Prior art keywords: alpha; cathepsin; therapeutic agents; aminoketone derivatives; cancer
Prior art date: 1992-12-25

Application number

DK93120432T

Other languages

English (en)

Inventor

Ando Ryoichi

Sakaki Toshiro

Morinaka Yasuhiro

Takahashi Chizuko

Tamao Yoshikuni

Original Assignee

Mitsubishi Chem Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-25

Filing date

1993-12-17

Publication date

1999-06-14

1993-12-17 Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp

1999-06-14 Application granted granted Critical

1999-06-14 Publication of DK0603769T3 publication Critical patent/DK0603769T3/da

Links

239000003814 drug Substances 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002027 Amyotrophy Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
108010032088 Calpain Proteins 0.000 abstract 1
102000007590 Calpain Human genes 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
108090000712 Cathepsin B Proteins 0.000 abstract 1
102000004225 Cathepsin B Human genes 0.000 abstract 1
108090000619 Cathepsin H Proteins 0.000 abstract 1
102000004175 Cathepsin H Human genes 0.000 abstract 1
108090000624 Cathepsin L Proteins 0.000 abstract 1
102000004172 Cathepsin L Human genes 0.000 abstract 1
208000012661 Dyskinesia Diseases 0.000 abstract 1
208000037147 Hypercalcaemia Diseases 0.000 abstract 1
206010061216 Infarction Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
108090000526 Papain Proteins 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
206010051482 Prostatomegaly Diseases 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
101710097834 Thiol protease Proteins 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
238000002835 absorbance Methods 0.000 abstract 1
230000002776 aggregation Effects 0.000 abstract 1
238000004220 aggregation Methods 0.000 abstract 1
201000008275 breast carcinoma Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000005907 cancer growth Effects 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000000170 cell membrane Anatomy 0.000 abstract 1
230000000148 hypercalcaemia Effects 0.000 abstract 1
208000030915 hypercalcemia disease Diseases 0.000 abstract 1
230000007574 infarction Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
235000019834 papain Nutrition 0.000 abstract 1
229940055729 papain Drugs 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
230000035699 permeability Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK93120432T 1992-12-25 1993-12-17 Alfa-aminoketonderivater DK0603769T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP34692792		1992-12-25

Publications (1)

Publication Number	Publication Date
DK0603769T3 true DK0603769T3 (da)	1999-06-14

Family

ID=18386761

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93120432T DK0603769T3 (da)	1992-12-25	1993-12-17	Alfa-aminoketonderivater

Country Status (8)

Country	Link
US (1)	US5422359A (da)
EP (1)	EP0603769B1 (da)
JP (1)	JPH0770058A (da)
AT (1)	ATE171171T1 (da)
CA (1)	CA2111931A1 (da)
DE (1)	DE69321087T2 (da)
DK (1)	DK0603769T3 (da)
ES (1)	ES2124281T3 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5498616A (en) *	1994-11-04	1996-03-12	Cephalon, Inc.	Cysteine protease and serine protease inhibitors
CA2200964A1 (en) *	1994-11-24	1996-05-30	Takeda Chemical Industries, Ltd.	Alpha-ketoamide derivatives as cathepsin l inhibitor
US5691368A (en) *	1995-01-11	1997-11-25	Hoechst Marion Roussel, Inc.	Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5679680A (en) *	1995-02-16	1997-10-21	Warner-Lambert Company	α-substituted hydrazides having calpain inhibitory activity
CA2215211A1 (en) *	1995-03-31	1996-10-03	Takeda Chemical Industries, Ltd.	Cysteine protease inhibitor
SK48198A3 (en)	1995-10-30	1998-10-07	Smithkline Beecham Corp	Cathepsin k molecule, a peptid being bonded to the hollow of active positon of cathepsin k, a composition, method for identification of inhibiting compound and inhibitors being competitively bonded to the active position of cathepsin k
WO1997016433A1 (en) *	1995-10-30	1997-05-09	Smithkline Beecham Corporation	Protease inhibitors
US6586466B2 (en)	1995-10-30	2003-07-01	Smithkline Beecham Corporation	Carbohydrazide-protease inhibitors
US5733911A (en) *	1996-01-26	1998-03-31	Hitachi Chemical Co., Ltd.	Method for inducing death of neoplastic cells using piperazne derivatives
US5925633A (en) *	1996-03-06	1999-07-20	Synphar Laboraties, Inc.	3-Substituted-4-oxa-1-azabicyclo 3,2,0!heptan-7-one as cysteine protease inhibitors
CA2251714A1 (en) *	1996-04-22	1997-10-30	Massachusetts Institute Of Technology	Suppression of immune response via inhibition of cathepsin s
AU4489397A (en)	1996-10-31	1998-05-22	Alcon Laboratories, Inc.	The use of calpain inhibitors to treat ocular neural pathology
US20030144175A1 (en) *	1998-12-23	2003-07-31	Smithkline Beecham Corporation	Protease inhibitors
US20030044399A1 (en) *	1998-12-23	2003-03-06	Smithkline Beecham Corporation	Method of treatment
KR100630986B1 (ko) *	1998-12-23	2006-10-09	스미스클라인 비참 코포레이션	프로테아제 억제제
UY26026A1 (es) *	1999-03-16	2000-10-31	Smithkline Beecham Corportion	Inhibidores de proteasas
US6534498B1 (en)	1999-11-10	2003-03-18	Smithkline Beecham Corporation	Protease inhibitors
WO2001034600A1 (en)	1999-11-10	2001-05-17	Smithkline Beecham Corporation	Protease inhibitors
JP2003513971A (ja)	1999-11-10	2003-04-15	スミスクライン・ビーチャム・コーポレイション	プロテア−ゼ阻害剤
KR20020067937A (ko) *	2000-01-26	2002-08-24	오노 야꾸힝 고교 가부시키가이샤	벤젠 축합 헤테로환 유도체 및 그 유도체를 유효성분으로서 함유하는 약제
AU2001243441B2 (en) *	2000-03-21	2004-11-25	Smithkline Beecham Corporation	Protease inhibitors
WO2002010768A2 (en) *	2000-07-31	2002-02-07	The Regents Of The University Of California	Model for alzheimer's disease and other neurodegenerative diseases
US20040038965A1 (en) *	2001-10-09	2004-02-26	Marquis, Jr. Robert W.	Protease inhibitors
WO2008045017A2 (en) *	2005-06-22	2008-04-17	Diamond Scott L	Sars and ebola inhibitors and use thereof, and methods for their discovery
JP4880685B2 (ja) *	2005-07-22	2012-02-22	ザプロクターアンドギャンブルカンパニー	薬物による不整脈の発生を低減するための組成物
JP2020002014A (ja) *	2018-06-25	2020-01-09	日本システム企画株式会社	阻害活性物及びその精製方法
WO2024018245A1 (en)	2022-07-22	2024-01-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en)	2023-01-20	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5055451A (en) *	1986-12-22	1991-10-08	Syntex Inc.	Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
JP3190431B2 (ja) *	1991-07-01	2001-07-23	三菱化学株式会社	ケトン誘導体

1993
- 1993-12-17 DK DK93120432T patent/DK0603769T3/da active
- 1993-12-17 AT AT93120432T patent/ATE171171T1/de not_active IP Right Cessation
- 1993-12-17 EP EP93120432A patent/EP0603769B1/en not_active Expired - Lifetime
- 1993-12-17 DE DE69321087T patent/DE69321087T2/de not_active Expired - Fee Related
- 1993-12-17 ES ES93120432T patent/ES2124281T3/es not_active Expired - Lifetime
- 1993-12-20 CA CA002111931A patent/CA2111931A1/en not_active Abandoned
- 1993-12-22 US US08/171,692 patent/US5422359A/en not_active Expired - Fee Related
- 1993-12-24 JP JP5328448A patent/JPH0770058A/ja active Pending

Also Published As

Publication number	Publication date
EP0603769B1 (en)	1998-09-16
CA2111931A1 (en)	1994-06-26
ATE171171T1 (de)	1998-10-15
EP0603769A1 (en)	1994-06-29
DE69321087D1 (de)	1998-10-22
US5422359A (en)	1995-06-06
DE69321087T2 (de)	1999-05-20
JPH0770058A (ja)	1995-03-14
ES2124281T3 (es)	1999-02-01

Publication	Publication Date	Title
DK0603769T3 (da)	1999-06-14	Alfa-aminoketonderivater
GR3026734T3 (en)	1998-07-31	Aminoketone derivatives.
DE69706566D1 (de)	2001-10-11	Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
HU9201700D0 (en)	1992-08-28	Oral preparations for treating internal inflammations and process for its production
DE69815122D1 (de)	2003-07-03	Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
EP0945135A3 (en)	1999-12-29	Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
BG105435A (en)	2001-12-29	Stable liquid formulations of botulinum toxin
SI0725779T1 (da)	2001-12-31
PL323798A1 (en)	1998-04-27	Application of derivatives of vitamin d4 in treating skin diseases
DE3582439D1 (de)	1991-05-16	Mittel zur behandlung von herzerkrankungen.
TW362973B (en)	1999-07-01	Use of 2-anino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a composition having an antidepressant activity
ATE205712T1 (de)	2001-10-15	Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
IL81573A (en)	1991-04-15	Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
MY139368A (en)	2009-09-30	Novel cyclohexyl sulphones
DE3850154D1 (de)	1994-07-21	Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE162076T1 (de)	1998-01-15	Verwendung von nadh und nadph zur herstellung eines arzneimittels zur behandlung von morbus alzheimer
EA200000242A1 (ru)	2000-08-28	Применение фанхинона для лечения болезни альцгеймера
DE68916777D1 (de)	1994-08-18	Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE69729201D1 (de)	2004-06-24	Sulfonfluoride zur behandlung von der alzheimerischen krankheit
AP2000002004A0 (en)	2000-12-31	Method of treatment for dermatological disorders and compositions therefor.
ATE499946T1 (de)	2011-03-15	Verwendung von hgf für die behandlung von ischämischen erkrankungen der extremitäten
Jansen et al.	1974	Heart deaths and fluoridation
DE69233773D1 (de)	2009-11-19	Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
ATE186640T1 (de)	1999-12-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ATE66815T1 (de)	1991-09-15	Arzneimittel enthaltend einen aus den peyer'schen plaques hergestellten organextrakt zur behandlung bei diabetes mellitus und pankreatitis.